Sue Sha

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Sue Sha, Damayanthi Devineni, A. Ghosh et al. · Diabetes Obesity and Metabolism · 2011 · 294 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

David Polidori, Sue Sha, Sunder Mudaliar et al. · Diabetes Care · 2013 · 263 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Sue Sha, David Polidori, Tim Heise et al. · Diabetes Obesity and Metabolism · 2014 · 244 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Kenneth Cusi, Fernando Bril, Diana Barb et al. · Diabetes Obesity and Metabolism · 2018 · 197 citations

Medicine, Endocrinology, Pharmacology +17

Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin

Klaus Rave, S. Bott, Lutz Heinemann et al. · Diabetes Care · 2005 · 171 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14